Right drug
Right dose
Right patient
Optimal Medication Regimen
testing kit Your healthcare provider will order a PGx test for you if appropriate
Once you receive your collection kit, you will collect your DNA sample via buccal (cheek) swab, extracted gDNA sources, or whole blood sample
You will send the DNA sample to Innovative Gx Laboratories (IGx)
The lab analyzes the data and generates a report
Your healthcare provider will review the test results with you during a post-PGx consultation and develop a personalized treatment strategy
The PGxSmartmeds+ report is designed with 5 simple classifications that clinicians can use to guide medication choices.
Among the genes analyzed, no genetic variants or metabolic interactions were identified that would suggest a need for increased caution or dose adjustments for medications in this category.
One or more genetic variants or metabolic interactions have been identified that would indicate a need for increased caution, dose adjustment or selection of alternate medication.
Refers to gene-drug pairs in which the interaction between a drug and one or several genes may result in a mild adverse drug reaction(s) and lack of efficacy.
Gene-drug pairs in a negative drug response (adverse drug reaction(s) and lack of efficacy) might be preventable by adjusting the medication to the patient’s individual needs based on pharmacogenomic results and any other non-genetic factors of your knowledge.
In a study published in JAMA Oncology, researchers conducted pharmacogenetic testing on 92 patients with advanced cancer who were being treated with the chemotherapy drug irinotecan. The results showed that patients with a certain genetic variant had a higher risk of experiencing severe side effects, which allowed clinicians to adjust the dose or switch to a different medication [1].
A case study published in the Journal of Clinical Psychiatry involved a patient with a major depressive disorder who had failed to respond to multiple antidepressant medications. Pharmacogenetic testing revealed that the patient had a genetic variant associated with poor metabolism of certain antidepressants, leading to a medication change and improved symptom control [2].
In another study, researchers conducted pharmacogenetic testing on over 10,000 patients as part of the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program. The testing helped identify patients at increased risk of adverse drug reactions or who were unlikely to respond to certain medications, allowing for more personalized treatment approaches [3].
[1] Innocenti F, Owzar K, Cox N, et al. A Genotype-Directed Dosing Study of Irinotecan in Patients With Advanced Cancer. JAMA Oncol. 2017;3(12):170078. doi:10.1001/jamaoncol.2017.0078
[2] Winner JG, Carhart JM, Altar CA, Goldfarb S. A pilot study examining the effects of genotype-guided dosing of duloxetine on pain control in patients undergoing total knee arthroplasty. J Pain Res. 2015;8:363-372. doi:10.2147/JPR.S87268
[3] Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423-431. doi:10.1038/clpt.2013.213
67 Genes
664 Variants
294 Medications
NGS + QPCR
PGxSmartmeds+ Report
We’ve got you covered! Our Chief Medical Consultant is available for 24/7 consultation to help you navigate your results and answer any questions you may have. With our expert guidance, you can gain deeper insights into your medication metabolism and make informed decisions about your healthcare.
Contact us today to learn more about our PGxSmartMeds+ test and our consultation services!
The FDA recommends/requires PGx testing prior to taking a new medication your doctor may prescribe.
You are on multiple medications.
You have tried multiple medications/dosages without finding one that works well for you.
You have a personal or family history of serious side effects.
You may require a higher or lower than usual dose of certain medications.
Your medication stops working when you eat certain foods (spinach), take certain supplements (St. John’s Wort), or drink certain juices (grapefruit juice).
Your medication has stopped working as usual after your healthcare provider prescribed an additional medication.
Covering 22 theraputic areas and 294 medications
| Therapeutic Area | Drug Class | Mechanism of Action | Generic Name | Brand Name | Gene(s) | Source(s) | Clinical Utility |
| Anesthesiology | Depolarizing Neuromuscular Blocker Agent | Cholinergic Receptor Agonist | Succinylcholine | Anectine; Quelicin | RYR1/CACNA1S | FDA/CPIC | Actionable |
| BCHE | FDA | Actionable | |||||
| General Inhalation Anesthetic | Positive Ionic GABA Receptor Stimulator | Desflurane | Suprane | RYR1/CACNA1S | FDA/CPIC | Actionable | |
| Enflurane | Ethrane | RYR1/CACNA1S | FDA/CPIC | Actionable | |||
| Halothane | International use only | RYR1/ CACNA1S | CPIC | Actionable | |||
| Isoflurane | Forane; Terrell | RYR1/CACNA1S | FDA/CPIC | Actionable | |||
| Methoxyflurane | International use only | RYR1/CACNA1S | CPIC | Actionable | |||
| Sevoflurane | Ultane | RYR1/CACNA1S | FDA/CPIC | Actionable | |||
| Local Anesthetic | Generation and Conduction of Nerve Impulse Blocker | Articaine and Epinephrine | Ultacan; Ultacan Forte | G6PD | FDA | Actionable | |
| Sodium Influx Inhibitor | Chloroprocaine | Clorotekal; Nesacaine | G6PD | FDA | Actionable | ||
| Lidocaine and Tetracaine | Synera | G6PD | FDA | Actionable | |||
| Mepivacaine | Carbocaine; Polocaine | G6PD | FDA | Actionable | |||
| Oxymetazoline and Tetracaine | Kovanaze | G6PD | FDA | Actionable | |||
| Ropivacaine | Naropin | G6PD | FDA | Actionable | |||
| Ionic Flux Inhibitor | Lidocaine and Prilocaine | Lidopril; Prikaan; Oraqix; AgonEaze | G6PD | FDA | Actionable | ||
| Sodium Channel Blocker and Norepinephrine Uptake Inhibitor | Cocaine | C-Topical; Goprelto; Numbrino | DRD2 | PharmGKB | Associative | ||
| Sodium Channel Blocker | Lidocaine | Xylocaine; Lidomark 1/5; Lidomark 2/5; P-Care X; Akten; Lidoderm; LMX 4; LMX 5; Topicaine; Lubricaine | G6PD | CPIC | Informative | ||
| Musculoskeletal Agent | Non-Depolarizing Neuromuscular Blocker | Mivacurium | Mivacron | BCHE | FDA | Actionable |
| Cardiology | Alpha and Beta Adrenergic Blocker | Nonselective Beta Adrenergic Blocker and Alpha 1 Adrenergic Blocker | Carvedilol | Coreg | CYP2D6 | FDA | Actionable |
| Labetalol | Normodyne; Trandate | CYP2D6 | CPIC | Informative | |||
| Antiarrhythmic Agent | Sodium and Potassium ATPase Pump Inhibitor | Digoxin | Digitek; Digox; Lanoxin; Lanoxin Pediatric | ABCB1 | PharmGKB | Associative | |
| Sodium and Potassium Channel Inhibitor | Quinidine | Available only as generic | CYP2D6 | FDA | Actionable | ||
| Procainamide | International use only | NAT2 | FDA | Actionable | |||
| Sodium Channel Blocker | Flecainide | Tambocor | CYP2D6 | CPIC/PharmGKB | Informative | ||
| Lidocaine | Xylocaine; Lidomark 1/5; Lidomark 2/5; P-Care X; Akten; Lidoderm; LMX 4; LMX 5; Topicaine; Lubricaine | G6PD | CPIC | Informative | |||
| Propafenone | Rythmol SR | CYP2D6 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Anticoagulant | Synthesis of Vitamin K-Dependent Coagulation Factors II, VII, IX, and X, Protein C and S Inhibitor | Warfarin | Coumadin; Jantoven | CYP2C9/VKORC1/CYP4F2/CYP2C | FDA/CPIC | Actionable | |
| Acenocoumarol | International use only | CYP2C9 | CPIC/PharmGKB | Informative | |||
| CYP4F2 | CPIC/PharmGKB | Informative | |||||
| VKORC1 | PharmGKB | Informative | |||||
| Phenprocoumon | International use only | VKORC1 | PharmGKB | Informative | |||
| CYP4F2 | CPIC | Informative | |||||
| Antihypertensive | Angiotensin II Receptor Blocker | Irbesartan | Avapro | CYP2C9 | PharmGKB | Associative | |
| Losartan | Cozaar | CYP2C9 | PharmGKB | Associative | |||
| Angiotensin Converting Enzyme Inhibitor | Captopril | Capoten | ACE | PharmGKB | Informative | ||
| Benazepril | Lotensin | ACE | PharmGKB | Associative | |||
| Antilipemic Agent | HMG-CoA Reductase Inhibitor | Simvastatin | Zocor | ABCB1 | PharmGKB | Associative | |
| CYP3A4 | FDA | Informative | |||||
| SLCO1B1/CYP2C9 | FDA/CPIC | Actionable | |||||
| APOE | PharmGKB | Associative | |||||
| Rosuvastatin | Crestor; Ezallor Sprinkle | SLCO1B1/CYP2C9/ABCG2 | FDA/CPIC | Actionable | |||
| APOE | PharmGKB | Associative | |||||
| Lovastatin | Altoprev; Mevacor | CYP3A4 | FDA | Informative | |||
| APOE | PharmGKB | Associative | |||||
| SLCO1B1/CYP2C9 | CPIC | Actionable | |||||
| Atorvastatin | Lipitor | APOE | PharmGKB | Informative | |||
| CYP3A4 | FDA | Informative | |||||
| KIF6 | PharmGKB | Associative | |||||
| SLCO1B1/CYP2C9 | FDA/CPIC | Actionable | |||||
| Pravastatin | Pravachol | SLCO1B1/CYP2C9 | CPIC | Actionable | |||
| KIF6 | PharmGKB | Informative | |||||
| APOE | PharmGKB | Associative | |||||
| Cerivastatin | International use only | SLCO1B1 | PharmGKB | Associative | |||
| APOE | PharmGKB | Associative | |||||
| Fluvastatin | Lescol | APOE | PharmGKB | Associative | |||
| SLCO1B1/CYP2C9 | CPIC | Actionable | |||||
| Pitavastatin | Livalo; Zypitamag | APOE | PharmGKB | Associative | |||
| SLCO1B1/CYP2C9 | CPIC | Actionable | |||||
| Antiplatelet Agent | Prostaglandin Synthesis and Platelet Aggregation Inhibitor | Aspirin | Ecotrin; Bayer; Asctiptin; Durlaza | CYP2C9 | CPIC | Actionable | |
| G6PD | CPIC | Informative | |||||
| LTC4S | PharmGKB | Associative | |||||
| PTGS1 | PharmGKB | Associative | |||||
| P2Y12 Inhibitor | Prasugrel | Effient | CYP2C19/CYP2C9/CYP3A5/CYP2B6 | FDA | Actionable | ||
| Clopidogrel | Plavix | CYP2C19 | FDA/CPIC | Actionable | |||
| CES1 | PharmGKB | Informative | |||||
| Ticagrelor | Brilinta | CYP2C19 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Antithrombotic Agent | Selective Factor Xa Inhibitor | Rivaroxaban | Xarelto | Factor V | FDA | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Beta-Blocker | Beta-1 Adrenergic Receptor Antagonist | Metoprolol | Lopressor; Toprol XL | CYP2D6 | FDA | Actionable | |
| Nebivolol | Bystolic | CYP2D6 | FDA | Actionable | |||
| Nonselective Beta-Adrenergic Receptor Antagonist | Timolol | Betimol | CYP2D6 | CPIC/PharmGKB | |||
| Propranolol | Inderal; Inderal LA; InnoPran XL; Propranolol HCl Intensol; Inderal XL; Hemangeol | CYP2D6 | FDA | Actionable | |||
| Diuretic | Sodium and Chloride Reabsorption Inhibitor | Furosemide | Lasix | ADD1 | PharmGKB | Associative | |
| Mineralocorticoid (Aldosterone) Receptor Antagonist | Spironolactone | Aldactone | ADD1 | PharmGKB | Associative | ||
| Sodium Reabsorption Inhibitor | Hydrochlorothiazide | Microzide | ADD1 | PharmGKB | Informative | ||
| NEDD4L | PharmGKB | Informative | |||||
| Peripheral Vasodilator | Calcium Channel Blocker | Hydralazine | Apresoline | NAT2 | FDA | Actionable |
| Dental | Cholinergic Agonist | Cholinergic Receptor Agonist | Cevimeline | Evoxac | CYP2D6 | FDA | Actionable |
| CYP3A4 | FDA | Informative |
| Dermatology | Antibiotic | Para-Aminobenzoic Acid Competitive Inhibitor | Dapsone | Aczone | G6PD | FDA | Actionable |
| Antineoplastic Agent, Antimetabolite | DNA and RNA Synthesis Inhibitor | Fluorouracil | Adrucil; Carac; Efudex; Fluoroplex | DPYD | FDA/CPIC | Actionable | |
| GSTP1 | PharmGKB | Associative | |||||
| NQO1 | PharmGKB | Associative | |||||
| Dermatological Agent | Serotonin and Norepinephrine Reuptake Inhibitor, Histamine Receptor Antagonist | Doxepin | Silenor; Zonalon; Sinequan; Prudoxin | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |
| Disease Modifier | Tumor Necrosis Factor Inhibitor | Etanercept | Enbrel | TNF | PharmGKB | Informative | |
| Immunosuppressant Agent | Calcineurin Inhibitor | Tacrolimus | Astagraf XL; Prograf; Protopic; Envarsus XR | CYP3A5 | FDA/CPIC | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Monoclonal Antibody | Tumor Necrosis Factor Inhibitor | Adalimumab | Humira | TNF | PharmGKB | Associative | |
| Infliximab | Remicade | TNF | PharmGKB | Associative | |||
| Sulfonamide Antibiotic | Para-Aminobenzoic Acid (PABA) Competitive Antagonist and Enzyme Dihydropteroate Synthetase Blocker | Sulfacetamide | Bleph-10; Klaron; Ovace; Sodium Sulfacetamide Wash | G6PD | CPIC | Informative |
| Endocrinology | Endocrine Metabolic Agent | Glucosylceramide Synthase Inhibitor | Eliglustat | Cerdelga | CYP2D6 | FDA | Actionable |
| CYP3A4 | FDA | Informative | |||||
| Sulfonylurea | Insulin Release Stimulator | Chlorpropamide | Diabinese | G6PD | FDA | Actionable | |
| Glimepiride | Amaryl | CYP2C9 | FDA | Actionable | |||
| G6PD | FDA | Actionable | |||||
| Glyburide | Diabeta; Micronase; Glynase | G6PD | FDA | Actionable | |||
| Glipizide | glipiZIDE XL; Glucotrol XL | G6PD | FDA | Actionable | |||
| Tolazamide | Tolinase | G6PD | FDA | Actionable | |||
| Tolbutamide | Tol-Tab | G6PD | FDA | Actionable | |||
| Thiazolidinedione | Peroxisome Proliferator-Activated Receptor Gamma Agonist | Rosiglitazone | Avandia | CYP2C8 | PharmGKB | Associative |
| Gastroenterology | Monoclonal Antibody | Tumor Necrosis Factor Inhibitor | Adalimumab | Humira | TNF | PharmGKB | Associative |
| Infliximab | Remicade | TNF | PharmGKB | Associative | |||
| 5-Aminosalicylic Acid Derivative | Local Chemical Mediator of Inflammatory Response Modulator and TNF Inhibitor | Sulfasalazine | Azulfidine | NAT2/G6PD | FDA | Actionable | |
| Cyclooxygenase and Prostaglandin Synthesis Blocker | Mesalazine | Apriso; Asacol HD; Canasa; Delzicol; Lialda; Pentasa; Rowasa; SfRowasa | G6PD | CPIC | Informative | ||
| Acid Reducing Agent | Proton Pump Inhibitor | Dexlansoprazole | Dexilant | CYP2C19 | FDA/CPIC | Actionable | |
| Esomeprazole | Nexium | CYP2C19 | FDA/CPIC | Actionable | |||
| Lansoprazole | Prevacid; Prevacid SoluTab | CYP2C19 | FDA/CPIC | Actionable | |||
| Omeprazole | Prilosec | CYP2C19 | FDA/CPIC | Actionable | |||
| Pantoprazole | Protonix | CYP2C19 | FDA/CPIC | Actionable | |||
| Rabeprazole | AcipHex | CYP2C19 | FDA/CPIC | Actionable | |||
| Antiemetic | Dopamine and Serotonin Receptors Blocker | Metoclopramide | Reglan | CYP2D6/G6PD | FDA | Actionable | |
| Cannabinoid Receptor Agonist | Dronabinol | Syndros; Marinol | CYP2C9 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| 5-HT3 Receptor Antagonist | Ondansetron | Zofran; Zuplenz | ABCB1 | PharmGKB | Associative | ||
| CYP2D6 | FDA/CPIC | Actionable | |||||
| CYP3A4 | FDA | Informative | |||||
| Tropisetron | International use only | CYP2D6 | CPIC | Actionable | |||
| Palonosetron | Aloxi | CYP2D6 | FDA | Actionable | |||
| H1 Receptor Antagonist | Meclizine | Antivert; Bonine; Dramamine Less Drowsy; Motion-Time; Travel Sickness; Travel-Easy | CYP2D6 | FDA | Actionable | ||
| Osmotic Laxative | Fluid Retention Enhancer | Ascorbic Acid, Peg-3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate | Moviprep | G6PD | FDA | Actionable |
| Gynecology | Contraceptive | Follicle-Stimulating Hormone and Luteinizing Hormone Inhibitor | Drospirenone and Ethinyl Estradiol | Jasmiel; Lo-Zumandimine; Loryna; Nikki; Ocella; Syeda; Vestura; Yasmin 28; YAZ; Zarah; Zumandimine | CYP2C19 | FDA | Actionable |
| Hormonal Contraceptives For Systemic Use | F5 | PharmGKB | Informative | ||||
| Endocrine Metabolic Agent | Gonadotropin-Releasing Hormone Antagonist | Elagolix | Orilissa | SLCO1B1 | FDA | Actionable | |
| Central Nervous System Agent | Mixed 5-HT1A Agonist and 5-HT2A Antagonist | Flibanserin | Addyi | CYP2C19 | FDA | Actionable |
| Hematology | Antidote | Nitric Oxide Synthase and Guanylate Cyclase Inhibitor | Methylene Blue | ProvayBlue; Urolene Blue | G6PD | FDA | Actionable |
| Colony Stimulating Factor | Thrombopoietin Receptor Agonist | Eltrombopag | Promacta | F5 | FDA | Actionable | |
| Avatrombopag | Doptelet | F2/F5 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| CYP2C9 | FDA | Actionable | |||||
| Lusutrombopag | Mulpleta | F2/F5 | FDA | Actionable |
| Immunology | Immunomodulatory Agent | Sphingosine-1 Phosphate Receptor Modulator | Siponimod | Mayzent | CYP2C9 | FDA | Actionable |
| CYP3A4 | FDA | Informative | |||||
| Cholinergic Agonist | Cholinergic Receptor Agonist | Cevimeline | Evoxac | CYP2D6 | FDA | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Immunosuppressant Agent | Calcineurin Inhibitor | Tacrolimus | Astagraf XL; Prograf; Protopic; Envarsus XR | CYP3A5 | FDA/CPIC | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Purine Antagonist | Azathioprine | Azasan; Imuran | TPMT/NUDT15 | FDA/CPIC | Actionable | ||
| Dihydrofolate Reductase Inhibitor | Methotrexate | Otrexup; Rasuvo; Trexall; Xatmet | ABCB1 | PharmGKB | Associative | ||
| MTHFR | PharmGKB | Informative | |||||
| ATIC | PharmGKB | Informative | |||||
| MTRR | PharmGKB | Associative | |||||
| TYMS | PharmGKB | Associative | |||||
| SLC19A1 | PharmGKB | Informative | |||||
| Calcineurin Inhibitor | Cyclosporine | Gengraf; Neoral; SanIMMUNE; Restasis; Cequa | CYP3A5 | PharmGKB | Associative | ||
| mTOR Kinase Inhibitor | Sirolimus | Rapamune | CYP3A5 | PharmGKB | Associative | ||
| Leukotriene Modifying Agent | Leukotriene Receptor Antagonist | Montelukast | Singulair | LTC4S | PharmGKB | Associative |
| Infectious Diseases | Antibiotic | Bacterial Cell Wall Inhibitor | Nitrofurantoin | Macrobid; Furadantin; Macrodantin | G6PD | FDA | Actionable |
| Protein Synthesis Inhibitor | Chloramphenicol | International use only | G6PD | CPIC | Informative | ||
| Para-Aminobenzoic Acid Competitive Antagonist | Dapsone | Aczone | G6PD | FDA | Actionable | ||
| Mafenide | Sulfamylon | G6PD | FDA | Actionable | |||
| Macrolide and Sulfonamide Antibiotic Combination | Bacterial Protein and Folic Acid Synthesis Inhibitor | Erythromycin and Sulfisoxazole | Pediazole; E.S.P. | G6PD | FDA | Actionable | |
| Antifungal Agent | Ergosterol Synthesis Inhibitor | Voriconazole | Vfend | CYP2C19 | FDA/CPIC | Actionable | |
| Antihepaciviral | NS3/4A Protease Inhibitor | Boceprevir | Victrelis | IFNL3/IFNL4 | FDA | Actionable | |
| Telaprevir | Incivek | IFNL3/IFNL4 | FDA | Actionable | |||
| Simeprevir | Olysio | IFNL3/IFNL4 | FDA | Actionable | |||
| Human Type 1 Interferon Receptor Agonist | Peginterferon Alfa-2A | Pegasys | IFNL3/IFNL4 | CPIC | Actionable | ||
| Peginterferon Alfa-2B | PegIntron; Sylatron | IFNL3/IFNL4 | FDA/CPIC | Actionable | |||
| ITPA | PharmGKB | Informative | |||||
| Recombinant Interferon Alfa-2B | Intron A | ITPA | PharmGKB | Associative | |||
| Replication of RNA and DNA Viruses Inhibitor | Ribavirin | Available only as generic | IFNL3/IFNL4 | CPIC | Actionable | ||
| ITPA | PharmGKB | Informative | |||||
| Antimalarial Agent | DNA and RNA Polymerase Inhibitor | Chloroquine | Aralen | G6PD | FDA | Actionable | |
| Plasmacytoid Dendritic Toll-Like Receptor Blocker | Hydroxychloroquine | Plaquenil | G6PD | FDA | Actionable | ||
| Sodium and Potassium Channel Inhibitor | Quinidine | Available only as generic | CYP2D6 | FDA | Actionable | ||
| Exoerythrocytic Stages of Plasmodium Ovale and P.Vivax Antagonist | Primaquine | Available only as generic | G6PD | FDA | Actionable | ||
| Liver Stages Including the Hypnozoite of Plasmodium Vivax Antagonist | Tafenoquine | Krintafel; Arakoda | G6PD | FDA | Actionable | ||
| Nucleic Acid Synthesis, Protein Synthesis, and Glycolysis in Plasmodium Falciparum Inhibitor | Quinine Sulfate | Qualaquin | CYP2D6/G6PD | FDA | Actionable | ||
| Antiretroviral | Nucleotide Reverse Transcriptase Inhibitor | Abacavir | Ziagen | HLA-B | FDA/CPIC | Actionable | |
| Tenofovir | Viread | ABCC4 | PharmGKB | Associative | |||
| Integrase Inhibitor | Dolutegravir | Tivicay | UGT1A1 | FDA | Actionable | ||
| Raltegravir | Isentress | UGT1A1 | FDA | Actionable | |||
| Non-Nucleoside Reverse Transcriptase Inhibitor | Efavirenz | Sustiva | CYP2B6 | FDA/CPIC | Actionable | ||
| Nevirapine | Viramune; Viramune XR | ABCB1 | PharmGKB | Associative | |||
| CYP2B6 | CPIC/PharmGKB | Informative | |||||
| Protease Inhibitor | Atazanavir and Ritonavir | Available only as generic | UGT1A1 | PharmGKB | Informative | ||
| Lopinavir | Available only as generic | SLCO1B1 | PharmGKB | Associative | |||
| Atazanavir | Reyataz | UGT1A1 | CPIC | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Antitubercular Agent | Mycolic Acid Synthesis Inhibitor | Isoniazid | Nydrazid | NAT2 | FDA | Actionable | |
| DNA-Dependent RNA Polymerase Activity in Susceptible Mycobacterium Tuberculosis Inhibitor, Mycolic Acid Synthesis Inhibitor | Rifampin, Isoniazid, and Pyrazinamide | Rifater | NAT2 | FDA | Actionable | ||
| Arabinosyl Transferase Inhibitor | Ethambutol | Myambutol | NAT2 | PharmGKB | Informative | ||
| Cephalosporin Third Generation | Cell Wall Synthesis Inhibitor | Ceftriaxone | Rocephin | G6PD | FDA | Actionable | |
| Sulfonamide Antibiotic | Folic Acid Synthesis Inhibitor | Sulfadiazine | Silvadene | G6PD | FDA | Actionable | |
| Sulfamethoxazole and Trimethoprim | Bactrim; Septra; Sulfatrim | NAT2/G6PD | FDA | Actionable | |||
| Para-Aminobenzoic Acid (PABA) Competitive Antagonist and Enzyme Dihydropteroate Synthetase Blocker | Sulfacetamide | Bleph-10; Klaron; Ovace; Sodium Sulfacetamide Wash | G6PD | CPIC | Informative | ||
| Dihydropteroate Synthetase Inhibitor | Sulfisoxazole | Gantrisin Pediatric; Truxazole | G6PD | CPIC | Informative | ||
| Quinolone | Bacterial Topoisomerase II (DNA Gyrase) and Topoisomerase IV Inhibitor | Norfloxacin | International use only | G6PD | CPIC | Informative | |
| Nalidixic Acid | NegGram | G6PD | FDA | Actionable | |||
| Penicillin | Cell Wall Synthesis Inhibitor | Flucloxacillin | International use only | HLA-B | PharmGKB | Informative | |
| Aminoglycoside | Protein Synthesis Inhibitor | Amikacin | Arikayce | MT-RNR1 | CPIC | Actionable | |
| Tobramycin | Tobrex; Bethkis; Kitabis Pak; Tobi; Tobi Podhaler | MT-RNR1 | CPIC | Actionable | |||
| Gentamicin | Gentak | MT-RNR1 | CPIC | Actionable | |||
| Kanamycin | International use only | MT-RNR1 | CPIC | Actionable | |||
| Paromomycin | Humatin | MT-RNR1 | CPIC | Actionable | |||
| Plazomicin | Zemdri | MT-RNR1 | CPIC | Actionable | |||
| Streptomycin | International use only | MT-RNR1 | CPIC | Actionable |
| Oncology | Antiandrogen | Androgen Uptake Inhibitor | Flutamide | Eulexin | G6PD | FDA | Actionable |
| Antiestrogen | Selective Estrogen Receptor Modulator | Tamoxifen | Soltamox | CYP2D6/F2/F5 | FDA/CPIC | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Antineoplastic Agent | DNA Synthesis Inhibitor | Cisplatin | Platinol-AQ | ERCC1 | PharmGKB | Associative | |
| MTHFR | PharmGKB | Associative | |||||
| TPMT | FDA | Actionable | |||||
| GSTP1 | PharmGKB | Associative | |||||
| Oxaliplatin | Eloxatin | ERCC1 | PharmGKB | Associative | |||
| GSTP1 | PharmGKB | Associative | |||||
| Carboplatin | Paraplatin | ERCC1 | PharmGKB | Associative | |||
| MTHFR | PharmGKB | Associative | |||||
| Cyclophosphamide | Available only as generic | GSTP1 | PharmGKB | Associative | |||
| Histone Deacetylase Inhibitor | Belinostat | Beleodaq | UGT1A1 | FDA | Actionable | ||
| Topoisomerase I Inhibitor | Irinotecan | Camptosar; Ovivyde | UGT1A1 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Anti-Trop-2 and Topoisomerase I Inhibitor | Sacituzumab Govitecan-hziy | Trodelvy | UGT1A1 | FDA | Actionable | ||
| BRAF Inhibitor | Dabrafenib | Tafinlar | CYP3A4 | FDA | Informative | ||
| G6PD | FDA | Actionable | |||||
| Fibroblast Growth Factor Receptor Kinase Inhibitor | Erdafitinib | Balversa | CYP2C9 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Tyrosine Kinase Inhibitor | Nilotinib | Tasigna | UGT1A1 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Pazopanib | Votrient | UGT1A1/HLA-B*5701 | FDA | Actionable | |||
| Epidermal Growth Factor Receptor Inhibitor | Gefitinib | Iressa | CYP2D6 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Topoisomerase II Inhibitor | Epirubicin | Ellence | GSTP1 | PharmGKB | Associative | ||
| Human Type 1 Interferon Receptor Agonist | Peginterferon Alfa-2B | PegIntron; Sylatron | IFNL3/IFNL4 | FDA/CPIC | Actionable | ||
| ITPA | PharmGKB | Informative | |||||
| Recombinant Interferon Alfa-2B | Intron A | ITPA | PharmGKB | Associative | |||
| Thymidylate Synthase Inhibitor | Tegafur | Available only as generic | DPYD | CPIC | Actionable | ||
| Poly (ADP-ribose) polymerase (PARP) inhibitor | Rucaparib | Rubraca | CYP1A2/CYP2D6 | FDA | Actionable | ||
| MEK-1 and MEK-2 Reversible Inhibitor | Trametinib | Mekinist | G6PD | FDA | Actionable | ||
| Binimetinib | Mektovi | UGT1A1 | FDA | Actionable | |||
| HIF-2-alpha Inhibitor | Belzutifan | Welireg | CYP2C19 | FDA | Actionable | ||
| Antineoplastic Agent, Antimetabolite | Capecitabine | Xeloda | DPYD | FDA/CPIC | Actionable | ||
| Fluorouracil | Adrucil; Carac; Efudex; Fluoroplex | DPYD | FDA/CPIC | Actionable | |||
| GSTP1 | PharmGKB | Associative | |||||
| NQO1 | PharmGKB | Associative | |||||
| Purine Antagonist | Mercaptopurine | Purinethol; Purixan | TPMT/NUDT15 | FDA/CPIC | Actionable | ||
| Thioguanine | Tabloid | TPMT/NUDT15 | FDA/CPIC | Actionable | |||
| Dihydrofolate Reductase Inhibitor | Methotrexate | Otrexup; Rasuvo; Trexall; Xatmet | ABCB1 | PharmGKB | Associative | ||
| MTHFR | PharmGKB | Informative | |||||
| ATIC | PharmGKB | Informative | |||||
| MTRR | PharmGKB | Associative | |||||
| TYMS | PharmGKB | Associative | |||||
| SLC19A1 | PharmGKB | Informative | |||||
| Urate-Oxidase Enzyme | Oxidation of Uric Acid to Allantoin Catalyst | Rasburicase | Elitek | G6PD | FDA/CPIC | Actionable |
| Ophthalmology | Antiglaucoma | Nonselective Beta-Adrenergic Receptor Antagonist | Timolol | Betimol | CYP2D6 | CPIC/PharmGKB | Informative |
| Prostaglandin F2-Alpha Analog | Latanoprost | Xalatan; Xelpros | PTGFR | PharmGKB | Associative | ||
| Ophthalmologic Agent | Calcineurin Inhibitor | Cyclosporine | Gengraf; Neoral; SanIMMUNE; Restasis; Cequa | CYP3A5 | PharmGKB | Associative |
| Pain Management | Non-Steroidal Anti-Inflammatory Drug | Selective COX-2 Inhibitor | Celecoxib | Celebrex | CYP2C9 | FDA/CPIC | Actionable |
| Lumiracoxib | International use only | CYP2C9 | CPIC | Actionable | |||
| Aceclofenac | International use only | CYP2C9 | CPIC | Actionable | |||
| Cyclooxygenase 1 and 2 Inhibitor | Flurbiprofen | Ansaid | CYP2C9 | FDA/CPIC | Actionable | ||
| Piroxicam | Feldene | CYP2C9 | FDA/CPIC | Actionable | |||
| Meloxicam | Anjeso; Mobic; Qmiiz ODT; Vivlodex | CYP2C9 | FDA/CPIC | Actionable | |||
| Ibuprofen | Addaprin; Advil Junior Strength; Advil Migraine; Advil; Caldolor; Childrens Advil; Childrens Motrin; Dyspel; Genpril; GoodSense Ibuprofen Childrens; GoodSense Ibuprofen; IBU; Ibuprofen Childrens; Infants Advil ; KS Ibuprofen; Motrin Childrens; Motrin IB; Motrin Infants Drops; NeoProfen; Provil | CYP2C9 | FDA/CPIC | Actionable | |||
| CYP2C8 | PharmGKB | Associative | |||||
| Lornoxicam | International use only | CYP2C9 | CPIC | Actionable | |||
| Tenoxicam | International use only | CYP2C9 | CPIC | Actionable | |||
| Diclofenac | Diclozor; Flector; Pennsaid; Voltaren; Xrylix; Cambia; Zipsor; Zorvolex | CYP2C9 | CPIC | Actionable | |||
| Indomethacin | Indocin; Tivorbex | CYP2C9 | CPIC | Actionable | |||
| Naproxen | Aleve; EC-Naprosyn; EC-Naproxen; GoodSense Naproxen Sodium; Mediproxen; Naprelan; Naprosyn; Naproxen DR | CYP2C9 | CPIC | Actionable | |||
| Prostaglandin Synthesis and Platelet Aggregation Inhibitor | Aspirin | Ecotrin; Bayer; Asctiptin; Durlaza | CYP2C9 | CPIC | Actionable | ||
| G6PD | CPIC | Informative | |||||
| LTC4S | PharmGKB | Associative | |||||
| PTGS1 | PharmGKB | Associative | |||||
| Prostaglandin Synthesis Inhibitor | Metamizole | International use only | CYP2C9 | CPIC | Actionable | ||
| Opioid | MU-Opioid Receptor Agonist and Norepinephrine and Serotonin Reuptake Inhibitor | Tramadol | Ultram; ConZip | CYP2D6/CYP3A4/CYP2B6/COMT/OPRM1 | FDA/CPIC | Actionable | |
| MU-Opioid Receptor Agonist and N-Methyl-D- Aspartate Receptor Antagonist | Methadone | Dolophine; Methadone HCL Intensol; Methadose; Diskets Dispersible | COMT/OPRM1/CYP2D6 | CPIC | Actionable | ||
| CYP2B6 | CPIC/PharmGKB | Informative | |||||
| MU-Opioid Receptor Agonist | Oxycodone | Oxaydo; OxyCONTIN; Roxicodone; Xtampza ER | COMT/OPRM1/CYP2D6 | CPIC | Actionable | ||
| Hydrocodone | Hysingla ER; Zohydro ER | CYP2D6/COMT/OPRM1 | CPIC | Actionable | |||
| Morphine | Arymo ER; Duramorph; Infumorph 200; Infumorph 500; Kadian; Mitigo; MorphaBond ER; MS Contin | COMT/OPRM1 | CPIC | Actionable | |||
| Sufentanil | Dsuvia; Sufenta | COMT/OPRM1 | CPIC | Actionable | |||
| Remifentanil | Ultiva | COMT/OPRM1 | CPIC | Actionable | |||
| Alfentanil | Alfenta | COMT/OPRM1 | CPIC | Actionable | |||
| Hydromorphone | Dilaudid | COMT/OPRM1 | CPIC | Actionable | |||
| Codeine | Available only as generic | CYP2D6/COMT/OPRM1 | FDA/CPIC | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Levomethadone | International use only | COMT/OPRM1 | CPIC | Actionable | |||
| Fentanyl | Abstral; Actiq; Duragesic; Fentora; Ionsys; Lazanda; Sublimaze; Subsys | COMT/OPRM1 | CPIC | Actionable | |||
| ABCB1 | PharmGKB | Associative | |||||
| CYP3A4 | PharmGKB | Informative | |||||
| Oliceridine | Olinvyk | CYP2D6 | FDA | Actionable | |||
| Heroin | Available only as generic | OPRM1 | PharmGKB | Associative | |||
| Partial MU-Opioid Receptor Agonist and Kappa-Opioid Receptor Antagonist | Buprenorphine | Belbuca; Buprenex; Butrans; Probuphine Implant Kit; Sublocade | COMT/OPRM1 | CPIC | Actionable | ||
| Opioid Anatagonist | Opioid Receptor Antagonist | Naloxone | Evzio; Narcan | OPRM1 | PharmGKB | Associative | |
| Naltrexone | Vivitrol | COMT/OPRM1 | CPIC | Actionable | |||
| Opioid Dependency | Alpha-2 Adrenergic Agonist | Lofexidine | Lucemyra | CYP2D6 | FDA | Actionable |
| Psychiatry | Antidepressant | Selective Serotonin Reuptake Inhibitor | Sertraline | Zoloft | CYP2C19 | CPIC | Actionable |
| Fluoxetine | Prozac; Sarafem | CYP2D6 | FDA | Actionable | |||
| Citalopram | Celexa | CYP2C19/CYP3A4/CYP2D6 | FDA/CPIC | Actionable | |||
| HTR2A | PharmGKB | Associative | |||||
| Escitalopram | Lexapro | CYP2C19/CYP3A4/CYP2D6 | FDA/CPIC | Actionable | |||
| Fluvoxamine | Luvox; Luvox CR | CYP2D6 | FDA/CPIC | Actionable | |||
| Paroxetine | Paxil; Pexeva; Brisdelle | CYP2D6 | FDA/CPIC | Actionable | |||
| HTR1A | PharmGKB | Associative | |||||
| Serotonin and Norepinephrine Reuptake Inhibitor | Duloxetine | Cymbalta; Drizalma Sprinkle | CYP2D6 | FDA | Actionable | ||
| Venlafaxine | Effexor | CYP2D6 | FDA | Actionable | |||
| Desvenlafaxine | Pristiq | CYP2D6 | FDA | Actionable | |||
| Serotonin and Norepinephrine Reuptake Inhibitor, and 5-HT2 and Alpha1 Receptor Antagonist | Nefazodone | Serzone | CYP2D6 | FDA | Actionable | ||
| Alpha-2 Adrenergic Antagonist, 5-HT2 and 5-HT3 Serotonin Receptor and H1 Histamine Antagonist, and Moderate Peripheral Alpha-1 Adrenergic and Muscarinic Antagonist | Mirtazapine | Remeron | CYP2D6 | CPIC/PharmGKB | Informative | ||
| 5-HT Reuptake Inhibitor, 5-HT1A Receptor Agonist, and 5-HT3 Receptor Antagonist | Vortioxetine | Trintellix | CYP2D6 | FDA | Actionable | ||
| Dopamine and Norepinephrine Reuptake Inhibitor | Bupropion | Aplenzin; Forfivo XL; Wellbutrin SR; Wellbutrin XL | CYP2B6 | CPIC/PharmGKB | Informative | ||
| Antipsychotic | D2 and 5-HT1A Receptor Partial Agonist and 5-HT2A Receptor Antagonist | Aripiprazole | Abilify | CYP2D6 | FDA | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| MC4R | PharmGKB | Associative | |||||
| Aripiprazole Lauroxil | Aristada; Aristada Initio | CYP2D6 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Brexpiprazole | Rexulti | CYP2D6 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Cariprazine | Vraylar | CYP2D6 | FDA | Actionable | |||
| Nonselective Postsynaptic Dopaminergic D2 Receptor Blocker | Haloperidol | Haldol | MC4R | PharmGKB | Associative | ||
| CYP2D6 | CPIC/PharmGKB | Informative | |||||
| Dopamine Receptor Antagonist | Amisulpride | Solian; Barhemsys | MC4R | PharmGKB | Associative | ||
| 5-HT2A and Dopamine-D2 Receptor Antagonist | Risperidone | Risperdal | CYP2D6 | FDA | Actionable | ||
| DRD2 | PharmGKB | Associative | |||||
| MC4R | PharmGKB | Associative | |||||
| Paliperidone | Invega | CYP2D6 | FDA | Actionable | |||
| MC4R | PharmGKB | Associative | |||||
| Quetiapine | Seroquel | MC4R | PharmGKB | Associative | |||
| CYP3A4 | PharmGKB | Informative | |||||
| Iloperidone | Fanapt | CYP2D6 | FDA | Actionable | |||
| CYP3A4 | FDA | Informative | |||||
| Serotonin Type 2A, Dopamine Type 2, Histamine H1 and Alpha Adrenergic, Cholinergic and Other Dopaminergic and Serotonergic Receptor Antagonist | Clozapine | Clozaril; Versacloz | CYP2D6 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| HTR2C | PharmGKB | Associative | |||||
| D1 and D2, Alpha 1 Adrenergic and 5-HT2 Receptor Antagonist | Zuclopenthixol | International use only | CYP2D6 | CPIC/PharmGKB | Informative | ||
| Serotonin 5-HT2A and 5-HT2C, Dopamine D1-4, Histamine H1 and Alpha 1-Adrenergic Receptor Antagonist | Olanzapine | Zyprexa; Zyprexa Relprevv; Zyrexa Zydis | HTR2C | PharmGKB | Associative | ||
| DRD2 | PharmGKB | Associative | |||||
| D2 Receptor Blocker | Perphenazine | Trilafon | CYP2D6 | FDA | Actionable | ||
| Thioridazine | Mellaril | CYP2D6 | FDA | Actionable | |||
| Central Dopamine Receptor Antagonist | Pimozide | Orap | CYP2D6 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Sleep Aid | Serotonin and Norepinephrine Reuptake Inhibitor, Histamine Receptor Antagonist | Doxepin | Silenor; Zonalon; Sinequan; Prudoxin | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |
| Central Nervous System Agent | Selective Norepinephrine Reuptake Inhibitor | Atomoxetine | Strattera | CYP2D6 | FDA/CPIC | Actionable | |
| Viloxazine | Qelbree | CYP2D6/SLCO1B1 | FDA | Actionable | |||
| Central Nervous System Stimulant | Norepinephrine and Dopamine Reuptake Inhibitor | Amphetamine | Dyanavel XR; Adzenys XR-ODT; Adzenys ER | CYP2D6 | FDA | Actionable | |
| Methylphenidate | Adhansia XR; Aptensio XR; Concerta; Daytrana; Jornay PM; Metadate ER; Methylin; QuilliChew ER; Quillivant XR; Relexxii; Ritalin | CYP2D6 | PharmGKB | Associative | |||
| Dopamine Reuptake Inhibitor | Modafinil | Provigil | CYP2D6 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Histamine-3 (H3) Receptor Antagonist/Inverse Agonist | Pitolisant | Wakix | CYP2D6 | FDA | Actionable | ||
| Tricyclic Antidepressant | Serotonin and Norepinephrine Reuptake Inhibitor, Histamine Receptor Antagonist | Doxepin | Silenor; Zonalon; Sinequan; Prudoxin | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |
| Norepinephrine and Serotonin Uptake Inhibitor | Clomipramine | Anafranil | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | ||
| Imipramine | Tofranil | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |||
| Trimipramine | Surmontil | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |||
| Amitriptyline | Elavil; Vanatrip | CYP2D6/CYP2C19 | FDA/CPIC | Actionable | |||
| Amoxapine | Asendin | CYP2D6 | FDA | Actionable | |||
| Desipramine | Norpramin | CYP2D6 | FDA/CPIC | Actionable | |||
| Protriptyline | Vivactil | CYP2D6 | FDA | Actionable | |||
| Norepinephrine and Serotonin Reuptake Inhibitor; Histamine, 5-Hydroxytryptamine, and Acetylcholine Receptor Blocker | Nortriptyline | Pamelor | CYP2D6 | FDA/CPIC | Actionable | ||
| Benzodiazepine | GABA-A Agonist | Diazepam | Valium; Diastat AcuDial; Diazepam Intensol; Diastat Pediatric | CYP2C19 | FDA | Actionable |
| Respiratory | Anticholinergic Agent | M3 Receptor Inhibitor | Umeclidinium | Incruse Ellipta | CYP2D6 | FDA | Actionable |
| Tiotropium | Spiriva HandiHaler; Spiriva Respimat | ADRB2 | PharmGKB | Associative | |||
| Bronchodilator | Long-Acting Beta2-Adrenergic Agonist | Arformoterol | Brovana | CYP2D6/UGT1A1 | FDA | Actionable | |
| Indacaterol | Arcapta Neohaler | UGT1A1 | FDA | Actionable | |||
| Salmeterol | Serevent Diskus | ADRB2 | PharmGKB | Informative | |||
| Short-Acting Beta2-Adrenergic Agonist | Albuterol | ProAir; Proventil; Ventolin | CRHR2 | PharmGKB | Associative | ||
| Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | CFTR Mediated Chloride Ion Transport Potentiator | Ivacaftor | Kalydeco | CFTR | FDA/CPIC/ACMG | Actionable | |
| Ivacaftor, Tezacaftor, and Elexacaftor | Trikafta | CFTR | FDA/ACMG | Actionable | |||
| Ivacaftor and Lumacaftor | Orkambi | CFTR | FDA/ACMG | Actionable | |||
| Ivacaftor and Tezacaftor | Symdeko | CFTR | FDA/ACMG | Actionable | |||
| Antitussive | N-Methyl-D-Aspartate (NMDA) Receptor Antagonist | Dextromethorphan | Robitussin; Delsym; Pediacare; Robafen | CYP2D6 | CPIC | Informative | |
| Leukotriene Modifying Agent | Leukotriene Receptor Antagonist | Montelukast | Singulair | LTC4S | PharmGKB | Associative |
| Rheumatology | 5-Aminosalicylic Acid Derivative | Local Chemical Mediator of Inflammatory Response Modulator and TNF Inhibitor | Sulfasalazine | Azulfidine | NAT2/G6PD | FDA | Actionable |
| Antigout Agent | Oxidation of Uric Acid to Allantoin Catalyst | Pegloticase | Krystexxa | G6PD | FDA | Actionable | |
| Urate Tubular Reabsorption Inhibitor | Probenecid | Benemid; Probalan | G6PD | FDA | Actionable | ||
| Xanthine Oxidase Inhibitor | Allopurinol | Zyloprim | HLA-B | FDA/CPIC | Actionable | ||
| ABCG2 | PharmGKB | Associative | |||||
| URAT1 Inhibitor | Lesinurad | Zurampic | CYP2C9 | FDA | Actionable | ||
| Antirheumatic | Purine Antagonist | Azathioprine | Azasan; Imuran | TPMT/NUDT15 | FDA/CPIC | Actionable | |
| Dihydrofolate Reductase Inhibitor | Methotrexate | Otrexup; Rasuvo; Trexall; Xatmet | ABCB1 | PharmGKB | Associative | ||
| MTHFR | PharmGKB | Informative | |||||
| ATIC | PharmGKB | Informative | |||||
| MTRR | PharmGKB | Associative | |||||
| TYMS | PharmGKB | Associative | |||||
| SLC19A1 | PharmGKB | Informative | |||||
| Janus Associated Kinase Inhibitor | Upadacitinib | Rinvoq | CYP2D6 | FDA | Actionable | ||
| CYP3A4 | FDA | Informative | |||||
| Disease Modifier | Tumor Necrosis Factor Inhibitor | Etanercept | Enbrel | TNF | PharmGKB | Informative | |
| Monoclonal Antibody | Tumor Necrosis Factor Inhibitor | Adalimumab | Humira | TNF | PharmGKB | Associative | |
| Infliximab | Remicade | TNF | PharmGKB | Associative | |||
| Non-Steroidal Anti-Inflammatory Drug | Selective COX-2 Inhibitor | Celecoxib | Celebrex | CYP2C9 | FDA/CPIC | Actionable | |
| Lumiracoxib | International use only | CYP2C9 | CPIC | Actionable | |||
| Aceclofenac | International use only | CYP2C9 | CPIC | Actionable | |||
| Cyclooxygenase 1 and 2 Inhibitor | Flurbiprofen | Ansaid | CYP2C9 | FDA/CPIC | Actionable | ||
| Piroxicam | Feldene | CYP2C9 | FDA/CPIC | Actionable | |||
| Meloxicam | Anjeso; Mobic; Qmiiz ODT; Vivlodex | CYP2C9 | FDA/CPIC | Actionable | |||
| Ibuprofen | Addaprin; Advil Junior Strength; Advil Migraine; Advil; Caldolor; Childrens Advil; Childrens Motrin; Dyspel; Genpril; GoodSense Ibuprofen Childrens; GoodSense Ibuprofen; IBU; Ibuprofen Childrens; Infants Advil ; KS Ibuprofen; Motrin Childrens; Motrin IB; Motrin Infants Drops; NeoProfen; Provil | CYP2C9 | FDA/CPIC | Actionable | |||
| CYP2C8 | PharmGKB | Associative | |||||
| Lornoxicam | International use only | CYP2C9 | CPIC | Actionable | |||
| Tenoxicam | International use only | CYP2C9 | CPIC | Actionable | |||
| Diclofenac | Diclozor; Flector; Pennsaid; Voltaren; Xrylix; Cambia; Zipsor; Zorvolex | CYP2C9 | CPIC | Actionable | |||
| Indomethacin | Indocin; Tivorbex | CYP2C9 | CPIC | Actionable | |||
| Naproxen | Aleve; EC-Naprosyn; EC-Naproxen; GoodSense Naproxen Sodium; Mediproxen; Naprelan; Naprosyn; Naproxen DR | CYP2C9 | CPIC | Actionable | |||
| Nabumetone | Relafen DS | CYP2C9 | CPIC | Actionable | |||
| Prostaglandin Synthesis and Platelet Aggregation Inhibitor | Aspirin | Ecotrin; Bayer; Asctiptin; Durlaza | CYP2C9 | CPIC | Actionable | ||
| G6PD | CPIC | Informative | |||||
| LTC4S | PharmGKB | Associative | |||||
| PTGS1 | PharmGKB | Associative | |||||
| Muscle Relaxant | Intraneuronal Activity in Descending Reticular Formation and Spinal Cord Suppressant | Carisoprodol | Soma; Vanadom | CYP2C19 | FDA | Actionable |
| Smoking Cessation | Smoking Cessation Aid | Stereo-Selective Nicotinic-Cholinergic Receptor Agonist | Nicotine | GoodSense Nicotine; Nicoderm CQ; Nicorelief; Nicorette Mini; Nicorette Starter Kit; Nicorette; Nicotine Mini; Nicotine Step 1; Nicotine Step 2; Nicotine Step 3; Nicotrol; Nicotrol NS; Thrive | COMT | PharmGKB | Associative |
| CHRNA5 | PharmGKB | Informative | |||||
| CYP2A6 | PharmGKB | Informative | |||||
| Dopamine and Norepinephrine Reuptake Inhibitor | Bupropion | Aplenzin; Forfivo XL; Wellbutrin SR; Wellbutrin XL | CYP2B6 | CPIC/PharmGKB | Informative |
| Toxicology | Antidote | Methemoglobin Binder | Sodium Nitrite | Nithiodote | G6PD | FDA | Actionable |
| Heavy Metal Chelator | Succimer | Chemet | G6PD | FDA | Actionable | ||
| Dimercaprol | Bal In Oil | G6PD | CPIC | Informative | |||
| Opioid Anatagonist | Opioid Receptor Antagonist | Naltrexone | Vivitrol | COMT/OPRM1 | CPIC | Actionable |
| Urology | Alpha-1 Blocker | Selective Alpha-1A Adrenoceptor Antagonist | Tamsulosin | Flomax | CYP2D6 | FDA | Actionable |
| CYP3A4 | FDA | Informative | |||||
| Anticholinergic Agent | Competitive Muscarinic Receptor Antagonist | Tolterodine | Detrol | CYP2D6 | FDA | Actionable | |
| CYP3A4 | FDA | Informative | |||||
| Fesoterodine | Toviaz | CYP2D6 | FDA | Actionable | |||
| Selective M3 Receptor Antagonist | Darifenacin | Enablex | CYP2D6 | FDA | Actionable | ||
| Genitourinary Agent | Beta-3 Adrenergic Receptor Agonist | Mirabegron | Myrbetriq | CYP2D6 | FDA | Actionable | |
| Vasodilator | Phosphodiesterase-5 Enzyme Inhibitor | Sildenafil | Viagra; Revatio | GNB3 | PharmGKB | Associative | |
| Analgesic Agent | Voltage-Gated Sodium Channel Inhibitor | Phenazopyridine | AZO Urinary Pain Relief; Pyridium; Urinary Pain Relief | G6PD | CPIC | Informative |
| Infectious Diseases / Ophthalmology / Otorhinolaryngology | Quinolone | Bacterial Topoisomerase II (DNA Gyrase) and Topoisomerase IV Inhibitor | Ciprofloxacin | Cipro; Ciloxan; Cetraxal; Otiprio | G6PD | CPIC | Informative |
| Supplements | Vitamins | Folic Acid Agonist | methylfolate | Deplin | MTHFR | CPIC | Informative |
| Infectious Diseases / Ophthalmology | Quinolone | Bacterial Topoisomerase II (DNA Gyrase) and Topoisomerase IV Inhibitor | Moxifloxacin | Avelox; Moxeza; Vigamox | G6PD | CPIC | Informative |
